Monitor the May 18, 2026 trial start for developments in the FIRDAPSE patent litigation. A delay reduces near-term downside risk but prolongs uncertainty around generic competition.
Price Chart
Executive Summary
Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date of a prior filing. The amendment confirms a court order delaying the bench trial with Hetero USA, Inc. over FIRDAPSE patent validity from March 23, 2026 to May 18, 2026. No other changes were made.
Key Facts
- Amendment No. 1 to Form 8-K filed to correct a scrivener's error in the signature date of the original March 18, 2026 filing.
- District Court for the District of New Jersey delayed the bench trial in the patent litigation with Hetero USA, Inc. from March 23, 2026 to May 18, 2026.
- The litigation concerns the validity of Catalyst's Orange Book-listed patents for FIRDAPSE, which expire in 2032, 2034, and 2037.
- No other changes were made to the original filing; the delay does not reflect a ruling on the merits of the case.
Financial Impact
No immediate financial impact disclosed. Trial delay extends uncertainty but avoids near-term risk of adverse ruling.
Risk Factors
- Adverse ruling in the patent trial could invalidate key FIRDAPSE patents and open the door to generic competition.
- Extended litigation increases legal expenses and delays resolution of market exclusivity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001193125-26-114764 |
| Document: 0001193125-26-114764-index-headers.html | 0001193125-26-114764 |
| Document: 0001193125-26-114764-index.html | 0001193125-26-114764 |
| Document: 0001193125-26-114764.txt | 0001193125-26-114764 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access